Chronic Insomnia Treatment: CBT-I, Sleep Hygiene and Medication Safety

Evidence reviewed: 8 November 2026. Insomnia involves difficulty falling asleep, staying asleep or returning to sleep, despite adequate opportunity for sleep, with resulting daytime problems. Short episodes are common, but chronic insomnia disorder generally involves symptoms at least three nights per week for at least three months. It is often treatable. The 2025 VA/DoD guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as the primary treatment, while explicitly recommending against sleep-hygiene advice as the sole treatment for chronic insomnia. Sleeping pills may have a role in selected patients, but are not a universal or permanent cure [1–3].

What is chronic insomnia disorder?

Insomnia may affect sleep onset, sleep maintenance or waking earlier than desired. The diagnosis emphasizes distress or daytime impairment, such as fatigue, concentration problems, irritability or reduced work performance, despite reasonable time and conditions for sleep. People can have insomnia even when a wearable reports a seemingly normal total sleep duration; subjective distress and function matter [1,2].

Short-term insomnia may follow stress, travel, pain, grief or an illness. Chronic insomnia can persist after the initial trigger settles because of conditioned arousal, irregular sleep habits and worry about not sleeping. The goal of treatment is not to force everyone to sleep an identical number of hours.

Common contributors and alternative diagnoses

Contributor What to assess
Stress, anxiety or depression Mood symptoms, racing thoughts, safety and functional impacts.
Obstructive sleep apnea (OSA) Loud snoring, witnessed breathing pauses, gasping, sleepiness, cardiometabolic risk.
Restless legs syndrome Uncomfortable urge to move legs in the evening, relieved by movement; iron status when indicated.
Pain, reflux, nocturia or other illness Symptoms that repeatedly disrupt sleep and need targeted treatment.
Medicines and substances Stimulants, some antidepressants, corticosteroids, caffeine, alcohol and nicotine.
Circadian-rhythm mismatch Shift work, irregular sleep timing, delayed sleep–wake phase.
Bipolar mania/hypomania Marked decreased need for sleep with increased energy or impulsivity, which differs from feeling exhausted but unable to sleep.

Persistent severe daytime sleepiness, dangerous drowsy driving, witnessed breathing pauses, or unusual nighttime behavior merits appropriate evaluation. A patient may have both insomnia and OSA; the conditions should not be assumed mutually exclusive [1].

How is insomnia assessed?

A clinician takes a sleep history covering bedtime, sleep latency, nighttime awakenings, waking time, schedule variation, naps, caffeine, medicines, snoring and coexisting health problems. A one- to two-week sleep diary is often helpful. Validated questionnaires, such as the Insomnia Severity Index (ISI), can track symptom burden and response.

Polysomnography is not required for every uncomplicated insomnia case. A sleep study may be appropriate if OSA, abnormal movements, parasomnia, narcolepsy or another sleep disorder is suspected, or when treatment has failed and a specific alternative condition needs evaluation [1,2]. Consumer wearables may help notice habits but cannot reliably diagnose every sleep disorder or replace clinical assessment.

Why CBT-I is the first-line treatment

CBT-I is a structured, multicomponent therapy that addresses the behaviors and expectations sustaining insomnia. The 2025 VA/DoD guideline gives a strong recommendation for CBT-I and suggests brief behavioral treatment for insomnia (BBT-I) when appropriate. It also suggests CBT-I rather than medicines as first-line care [1].

CBT-I generally includes stimulus control, time-in-bed scheduling or sleep restriction/compression, cognitive strategies and sleep-related education. Delivery may be individual, group or via a validated digital program with appropriate support. Many patients improve over several weeks and can retain benefits after structured treatment ends [1,3].

Stimulus control: rebuilding the bed–sleep connection

With insomnia, the bed may become associated with worry, alertness, clock-checking and frustration rather than sleepiness. CBT-I stimulus-control techniques commonly include:

  1. Go to bed when sleepy, rather than solely because the clock reaches a target time.
  2. Use the bed mainly for sleep and sex rather than extended working, scrolling or worrying.
  3. If awake for a prolonged period and growing frustrated, get out of bed briefly to do something quiet in dim lighting, then return when sleepy.
  4. Keep a consistent wake-up time, including weekends where feasible.
  5. Reduce compensatory long daytime naps when these undermine nighttime sleep.

The aim is not to make people check the clock precisely every 20 minutes. A therapist adapts the principles to caring duties, disability, chronic pain, shift work and other realities [1,3].

Sleep restriction and sleep compression

Time-in-bed restriction is a CBT-I technique that temporarily aligns time in bed with actual sleep, helping strengthen sleep drive and consolidate sleep. The schedule is then gradually expanded when sleep efficiency improves. It should not be confused with general advice to sleep less or with deliberately staying awake for days.

Professional guidance is important because sleep restriction can temporarily increase daytime sleepiness and may be inappropriate or require special modification for people with bipolar disorder, seizure disorders, high-risk driving or machinery work, significant fall risk, or certain untreated sleep disorders. A clinician may use gentler sleep compression instead. Do not self-prescribe extreme sleep deprivation.

Cognitive strategies for sleep-related worry

People with insomnia may develop beliefs such as “If I do not sleep eight hours tonight, tomorrow will be a disaster.” CBT-I helps test rigid predictions, reduce clock monitoring and develop a more realistic relationship with sleep. The goal is less pressure and arousal around bedtime, not pretending fatigue has no consequences.

Relaxation and stress management may help, but relaxation by itself is not necessarily adequate treatment for chronic insomnia. When depression, trauma symptoms or chronic pain contribute, they should receive appropriate care in parallel [1].

Sleep hygiene: useful but not enough alone

Good sleep habits support overall health, but repeating a list of tips without addressing conditioned insomnia is not equivalent to CBT-I. The 2025 VA/DoD guidance specifically advises against using sleep-hygiene education as the only treatment for chronic insomnia [1,3].

Habit Practical approach
Light and schedule Maintain a reasonably consistent wake time; seek suitable daytime light.
Caffeine Reduce or avoid it late in the day if it disrupts sleep; sensitivity varies.
Alcohol Do not use it as a sleeping aid; it can fragment sleep and worsen breathing problems.
Bedroom Keep the room comfortable, quiet and dark when possible.
Exercise Maintain regular physical activity with timing adjusted to personal tolerance.
Devices Reduce stimulating work and bright-screen exposure if they increase alertness.
Large meals Manage reflux or discomfort when eating late.

For someone with night-shift work, an infant, caregiving duties or a noisy environment, routines may need adaptation. Blaming someone for their sleep problem is not treatment; the clinician should identify realistic steps and appropriate therapy.

What if CBT-I is not available?

A validated digital CBT-I program, group-based therapy or brief behavioral treatment for insomnia may help expand access. The VA/DoD guideline suggests BBT-I where full CBT-I is difficult to obtain. Not all apps marketed as sleep coaching deliver evidence-based CBT-I; look for structured behavioral and cognitive components, clinically tested methods and clear safety guidance [1,3].

Which medicines may be used?

When CBT-I is unavailable, insufficient or not appropriate, a clinician may consider medication for selected patients, ideally with a defined plan for duration, monitoring, interactions and stopping. The 2025 VA/DoD guideline suggests several classes including low-dose doxepin, selected non-benzodiazepine hypnotics (Z-drugs) and dual orexin receptor antagonists, while suggesting against routine benzodiazepines, diphenhydramine, trazodone and antipsychotics for chronic insomnia [1].

Medicine type Examples or mechanism Important considerations
Low-dose doxepin Histamine H1 antagonism; particularly sleep-maintenance symptoms in eligible patients. Drug interactions and dose-specific anticholinergic/sedation differences.
Dual orexin receptor antagonists Suvorexant, lemborexant, daridorexant; reduce wake-promoting orexin signaling. Next-day sedation, interactions, contraindications such as narcolepsy and product-specific precautions.
Z-drugs Zolpidem, eszopiclone, zaleplon; act on GABA-A receptor signaling. Falls, next-day impairment, dependence, and FDA boxed warning for complex sleep behaviors with some agents.
Melatonin receptor agonist Ramelteon targets MT1/MT2 receptors. Evidence and guideline recommendation strength differ; not a guaranteed cure.
Antihistamines or antipsychotics used as sedatives Examples include diphenhydramine or off-label antipsychotics. Not recommended routinely because benefit is limited or harms are substantial.

Medication lists are not prescriptions. Product approvals and availability vary by country. Risks are greater when combined with alcohol, opioids or other sedatives. Driving or operating machinery while sedated is dangerous. People should not share prescription sleeping pills [1,2].

Why benzodiazepines, antihistamines and trazodone are not preferred

Benzodiazepines can cause tolerance, physical dependence, falls, cognitive impairment and rebound insomnia. First-generation antihistamines such as diphenhydramine can cause anticholinergic effects, next-day sedation and confusion, particularly in older adults. Trazodone is frequently prescribed off-label but is not recommended for routine primary insomnia treatment by the 2025 VA/DoD guidance [1].

The presence of depression or another condition requiring a drug can change the overall treatment plan, but sedation alone does not establish that a medicine is an effective or safe insomnia treatment.

Melatonin, supplements and herbal products

Melatonin can be useful for selected circadian rhythm problems, but evidence for unselected chronic insomnia is inconsistent. Supplement content may vary between manufacturers, especially in unregulated products. The 2025 VA/DoD guideline recommends against kava, and suggests against cannabis and its derivatives for chronic insomnia because of limited benefit and potential harms [1].

Large-dose combinations of melatonin, antihistamines and herbs are not safer simply because ingredients are marketed as “natural.” Patients should discuss supplements, pregnancy and medication interactions with a healthcare professional.

Insomnia, sleep apnea and nighttime breathing

A person with habitual snoring, witnessed apneas, waking while gasping, morning headaches or severe daytime sleepiness may need evaluation for obstructive sleep apnea. Sedatives may worsen breathing or increase impairment in some patients. OSA and insomnia may coexist, and both may require treatment. Do not assume a sleeping pill addresses untreated sleep apnea [1].

Special considerations: pregnancy, older age and mental illness

Pregnancy and breastfeeding require individualized risk assessment because medication safety data differ. In older adults, sedatives can increase falls, confusion and driving impairment; non-drug therapy is particularly valuable. In patients with bipolar disorder, aggressive sleep restriction may destabilize mood and needs specialist planning. Patients taking opioids, alcohol or other CNS depressants have increased risks with hypnotics [1,2].

When to seek professional help

  • Difficulty sleeping and daytime impairment persist for weeks or months.
  • There is dangerous daytime sleepiness, drowsy driving or suspected sleep apnea.
  • Sleep problems occur with severe depression, suicidal thoughts, mania or psychosis.
  • Repeated sedatives are needed or the dose seems to be escalating.
  • A sleep disorder may be linked to restless legs, pain, medication effects or irregular shift work.

Frequently asked questions

Can sleep hygiene alone cure chronic insomnia?

It may help some habits, but the 2025 VA/DoD guideline advises against sleep-hygiene education as the only treatment. Use CBT-I when feasible [1].

Is CBT-I simply learning to relax?

No. It includes stimulus control, time-in-bed scheduling, cognitive work and relapse prevention.

Should everyone limit time in bed as much as possible?

No. Sleep restriction must be individualized, especially with seizure risk, bipolar disorder, driving duties or other safety concerns.

Is diphenhydramine a good daily sleep medicine?

No. Routine use is discouraged because of limited sustained benefit and anticholinergic and sedation risks [1].

Do I need a sleep study?

Not routinely for uncomplicated insomnia. Testing is considered when another disorder such as OSA is suspected.

Are orexin antagonists non-sedating?

No. They affect wakefulness and can cause next-day impairment; follow prescribing precautions.

Key takeaways

CBT-I is the guideline-recommended first-line treatment for chronic insomnia. Sleep-hygiene habits help but are not sufficient alone. Look for treatable contributors such as sleep apnea, and use sleeping medicines only with individualized risk assessment, monitoring and a clear plan.

References

  1. US Department of Veterans Affairs and Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea. 2025.
  2. American Academy of Sleep Medicine. Behavioral and psychological treatments for chronic insomnia disorder in adults: clinical practice guideline. J Clin Sleep Med. 2021.
  3. US Department of Veterans Affairs. Behaviorally-based treatments for insomnia: a provider’s guide. 2025.
  4. US Food and Drug Administration. FDA boxed warning for complex sleep behaviors with selected insomnia medicines. FDA.

Medical disclaimer: Educational information only. Sleeping medicines and sleep-restriction protocols have important safety risks; seek individualized medical care. Suspected sleep apnea, severe daytime impairment, mania or immediate mental-health safety concerns require professional assessment.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *